400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / Cell Cycle / Microtubule/Tubulin / ABT-751
CAS No.: 141430-65-1
Synonyms: E7010
ABT-751 can inhibit microtubule polymerization through binding to β-tubulin on the colchine site.
生物活性
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT00297089 | Lung Cancer N... more >>SCLC Non-Small-Cell Lung Cancer Collapse << | Phase 1 Phase 2 | Completed | - | - |
NCT00439296 | Recurrent Pediatric ALL ... more >> Relapsed Pediatric ALL Acute Lymphoblastic Leukemia Refractory Pediatric ALL Collapse << | Phase 1 | Terminated(The study was stopp... more >>ed due to poor accrual and lack of funding.) Collapse << | - | United States, California ... more >> City of Hope Duarte, California, United States, 91010 Childrens Hospital Los Angeles Los Angeles, California, United States, 90027 Stanford University Medical Center Palo Alto, California, United States, 94304-1812 UCSF School of Medicine San Francisco, California, United States, 94143-0106 United States, Florida University of Miami Cancer Center Miami, Florida, United States, 33136 United States, Michigan C.S. Mott Children's Hospital Ann Arbor, Michigan, United States, 48109-0914 United States, Minnesota Childrens Hospital & Clinics of Minnesota Minneapolis, Minnesota, United States, 55404-4597 United States, New York New York University Medical Center New York, New York, United States, 10016 United States, Washington Seattle Children's Hospital Seattle, Washington, United States, 98105 Collapse << |
NCT00036959 | Brain and Central Nervous Syst... more >>em Tumors Childhood Germ Cell Tumor Extragonadal Germ Cell Tumor Kidney Cancer Liver Cancer Neuroblastoma Ovarian Cancer Sarcoma Unspecified Childhood Solid Tumor, Protocol Specific Collapse << | Phase 1 | Completed | - | United States, Illinois ... more >> Children's Memorial Hospital - Chicago Chicago, Illinois, United States, 60614 United States, Maryland Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office Bethesda, Maryland, United States, 20892-1182 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104-4318 Collapse << |
实验方案
技术信息
CAS号 | 141430-65-1 | 储存条件 |
|
|||||||||||||
分子式 | C18H17N3O4S | 运输 | 蓝冰 | |||||||||||||
分子量 | 371.41 | 别名 | E7010 | |||||||||||||
溶解度 |
|
动物实验配方 |
|
Cell Lines | Concentration | Assay Type | Time | Activity Description | Data Sources |
---|
A2780 cells | - | Cytotoxicity assay | 48-72 h | Cytotoxicity against human A2780 cells after 48 to 72 hrs by WAT-1 assay, IC50=0.17 μM | 21126027 |
A549 cells | - | Proliferation assay | 24 h | Antiproliferative activity against human A549 cells assessed as growth inhibition after 24 hrs by SRB assay, GI50=1.31 μM | 25468039 |
ACHN cells | - | Cytotoxicity assay | 48 h | Cytotoxicity against human ACHN cells after 48 hrs by MTT assay, IC50=2.13 μM | 24835786 |
DU145 cells | - | Proliferation assay | 24 h | Antiproliferative activity against human DU145 cells assessed as growth inhibition after 24 hrs by SRB assay, GI50=1.81 μM | 25468039 |
DU145 cells | - | Cytotoxicity assay | 48 h | Cytotoxicity against human DU145 cells after 48 hrs by MTT assay, GI50=1.81 μM | 24835786 |
H460 cells | - | Cytotoxicity assay | 72 h | Cytotoxicity against human H460 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay, IC50=0.2177 μM | 24106982 |
HCT116-C9 cell | - | Function assay | - | Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in HCT116-C9 cell line, IC50=0.9 μM | 12383017 |
HCT-15 cell | - | Proliferation assay | - | Antiproliferative activity against human colon carcinoma HCT-15 cell line(MDR(-)), IC50=0.34 μM | 11425534 |
HeLa cells | - | Cytotoxicity assay | 48-72 h | Cytotoxicity against human HeLa cells after 48 to 72 hrs by WAT-1 assay, IC50=0.27 μM | 21126027 |
Hep3B cells | - | Cytotoxicity assay | 48 h | Cytotoxicity against human Hep3B cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay, GI50=0.84 μM | 26241032 |
HT-29 cells | - | Proliferation assay | 72 h | Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay, IC50=0.21 μM | 23202849 |
HT-29 cells | - | Cytotoxicity assay | 72 h | Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay, IC50=0.3387 μM | 24106982 |
HT-29 cells | - | Cytotoxicity assay | 48 h | Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay, IC50=1.62 μM | 24835786 |
human A549 cells | - | Cytotoxicity assay | 48 h | Cytotoxicity against human A549 cells after 48 hrs by MTT assay, IC50=1.31 μM | 24835786 |
human A549 cells | - | Cytotoxicity assay | 48 h | Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay, GI50=5.33 μM | 26241032 |
human AsPC1 cells | - | Cytotoxicity assay | 48 h | Cytotoxicity against human AsPC1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay, GI50=4.11 μM | 26241032 |
human HL60 cells | - | Proliferation assay | - | Antiproliferative activity against human HL60 cells, IC50=0.34 μM | 17276056 |
human MCF7 cells | - | Proliferation assay | 24 h | Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 24 hrs by SRB assay, GI50=1.25 μM | 25468039 |
human PC3 cells | - | Cytotoxicity assay | 48 h | Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay, GI50=0.62 μM | 26241032 |
human SKBR3 cells | - | Growth inhibition assay | 48 h | Growth inhibition of human SKBR3 cells after 48 hrs by MTT assay, IC50=0.74 μM | 22850214 |
HUVEC | 100-1000 nM | Function assay | 4 h | Induction of vascular disrupting activity in HUVEC assessed as VEGF-induced tube formation at 100 to 1000 nM after 4 hrs by microscopic analysis | 24106982 |
Jurkat cells | - | Function assay | 24 h | Cell cycle arrest in human Jurkat cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis, IC50=0.16 μM | 21126027 |
KB cells | - | Cytotoxicity assay | 72 h | Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay, IC50=0.2513 μM | 24106982 |
KB-7d cells | - | Cytotoxicity assay | 72 h | Cytotoxicity against human KB-7d cells overexpressing MRP assessed as growth inhibition after 72 hrs by methylene blue staining-based assay, IC50=0.205 μM | 24106982 |
KB-S15 cells | - | Cytotoxicity assay | 72 h | Cytotoxicity against human KB-S15 cells overexpressing P-gp170/MDR assessed as growth inhibition after 72 hrs by methylene blue staining-based assay, IC50=0.206 μM | 24106982 |
KB-VIN10 cells | - | Cytotoxicity assay | 72 h | Cytotoxicity against human KB-VIN10 cells overexpressing P-gp170/MDR assessed as growth inhibition after 72 hrs by methylene blue staining-based assay, IC50=0.227 μM | 24106982 |
MCF7 cells | - | Cytotoxicity assay | 48 h | Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay, IC50=1.25 μM | 24835786 |
MDR1 cells | - | Cytotoxicity assay | 48-72 h | Cytotoxicity against human NCI-ADR-RES expressing MDR1 cells after 48 to 72 hrs by WAT-1 assay, IC50=0.29 μM | 21126027 |
MKN45 cells | - | Cytotoxicity assay | 72 h | Cytotoxicity against human MKN45 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay, IC50=0.166 μM | 24106982 |
NCI-H460 cell | - | Proliferation assay | - | Antiproliferative activity against human lung carcinoma NCI-H460 cell line (MDR(+)), IC50=0.35 μM | 11425534 |
P388 cell line | - | Function assay | 72 h | Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in P388 cell line, IC50=0.19 μM | 12383017 |
P388/4.0 r-M cell line | - | Function assay | 72 h | Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in P388/4.0 r-M cell line, IC50=15 μM | 12383017 |
SW620 cells | - | Cytotoxicity assay | 48-72 h | Cytotoxicity against human SW620 cells after 48 to 72 hrs by WAT-1 assay, IC50=0.19 μM | 21126027 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT00297089 | Lung Cancer N... more >>SCLC Non-Small-Cell Lung Cancer Collapse << | Phase 1 Phase 2 | Completed | - | - |
NCT00439296 | Recurrent Pediatric ALL ... more >> Relapsed Pediatric ALL Acute Lymphoblastic Leukemia Refractory Pediatric ALL Collapse << | Phase 1 | Terminated(The study was stopp... more >>ed due to poor accrual and lack of funding.) Collapse << | - | United States, California ... more >> City of Hope Duarte, California, United States, 91010 Childrens Hospital Los Angeles Los Angeles, California, United States, 90027 Stanford University Medical Center Palo Alto, California, United States, 94304-1812 UCSF School of Medicine San Francisco, California, United States, 94143-0106 United States, Florida University of Miami Cancer Center Miami, Florida, United States, 33136 United States, Michigan C.S. Mott Children's Hospital Ann Arbor, Michigan, United States, 48109-0914 United States, Minnesota Childrens Hospital & Clinics of Minnesota Minneapolis, Minnesota, United States, 55404-4597 United States, New York New York University Medical Center New York, New York, United States, 10016 United States, Washington Seattle Children's Hospital Seattle, Washington, United States, 98105 Collapse << |
NCT00036959 | Brain and Central Nervous Syst... more >>em Tumors Childhood Germ Cell Tumor Extragonadal Germ Cell Tumor Kidney Cancer Liver Cancer Neuroblastoma Ovarian Cancer Sarcoma Unspecified Childhood Solid Tumor, Protocol Specific Collapse << | Phase 1 | Completed | - | United States, Illinois ... more >> Children's Memorial Hospital - Chicago Chicago, Illinois, United States, 60614 United States, Maryland Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office Bethesda, Maryland, United States, 20892-1182 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104-4318 Collapse << |
NCT00073151 | Non-Small Cell Lung Cancer | Phase 2 | Completed | - | United States, Florida ... more >> Oncology Hematology Group of South Florida Miami, Florida, United States Florida Cancer Institute New Port Richey, Florida, United States United States, Illinois University of Chicago Medical Center Chicago, Illinois, United States, 60637-1460 United States, Maryland University of Maryland Greenbaum Cancer Center Baltimore, Maryland, United States, 21201-1595 United States, Missouri Oncology & Hematology Associates of Kansas City, PA Kansas City, Missouri, United States, 64111 Washington University School of Medicine St. Louis, Missouri, United States, 63110-1093 United States, New York Albany Regional Cancer Center Albany, New York, United States United States, North Carolina Raleigh Hematology Oncology Cary, North Carolina, United States United States, Ohio Dayton Oncology and Hematology Kettering, Ohio, United States United States, Oklahoma Cancer Care Associates Oklahoma City, Oklahoma, United States United States, South Carolina Cancer Centers of the Carolinas Greenville, South Carolina, United States United States, Tennessee West Cancer Clinic Memphis, Tennessee, United States, 38120 United States, Texas Texas Oncology Dallas, Texas, United States Texas Oncology Ft. Worth, Texas, United States United States, Washington Cancer Care Northwest Spokane, Washington, United States Northwest Cancer Specialists Vancouver, Washington, United States United States, Wisconsin University of Wisconsin Comprehensive Cancer Center Madison, Wisconsin, United States, 53792-5666 Collapse << |
NCT00073112 | Renal Cell Cancer | Phase 2 | Completed | - | - |
NCT00047489 | Hematological Malignancies | Phase 1 | Completed | - | United States, Texas ... more >> The University of Texas M.D. Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT00354562 | Lung Cancer N... more >>on-Small Cell Lung Cancer Collapse << | Phase 1 Phase 2 | Terminated | - | - |
NCT00063102 | Breast Cancer | Phase 2 | Completed | - | United States, Florida ... more >> Oncology-Hematology Group of South Florida Miami, Florida, United States, 33176 Clinical Research Network, Inc. Plantation, Florida, United States, 33324 United States, Georgia Georgia Cancer Specialists Atlanta, Georgia, United States United States, Illinois Northwestern University Medical School Division of Hematology/Oncology Chicago, Illinois, United States, 60611 United States, Indiana Indiana University Cancer Center Section of of Hemtology/Oncology Indiana Cancer Pavilion Indianapolis, Indiana, United States, 46202 Northern Indiana Cancer Research Consortium South Bend, Indiana, United States United States, Missouri Oncology & Hemotology Associates of Kansas City, PA Kansas City, Missouri, United States, 64111 United States, Texas Texas Oncology Dallas, Texas, United States Collapse << |
NCT00436852 | Disseminated Neuroblastoma ... more >> Recurrent Neuroblastoma Collapse << | Phase 2 | Active, not recruiting | - | United States, Alabama ... more >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, Illinois University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637-1470 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Michigan C S Mott Children's Hospital Ann Arbor, Michigan, United States, 48109 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, New York Columbia University Medical Center New York, New York, United States, 10032 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 Nationwide Children's Hospital Columbus, Ohio, United States, 43205 United States, Oregon Oregon Health and Science University Portland, Oregon, United States, 97239 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 United States, Texas Cook Children's Medical Center Fort Worth, Texas, United States, 76104 Canada, Ontario Hospital for Sick Children Toronto, Ontario, Canada, M5G 1X8 Collapse << |
NCT00073138 | Colorectal Cancer | Phase 2 | Completed | - | United States, California ... more >> University of Southern California Los Angeles, California, United States, 90089 Cancer Institute Medical Group Santa Monica, California, United States, 90095-3961 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611-5933 University of Chicago Medical Center Chicago, Illinois, United States, 60637 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Wisconsin University of Wisconsin Medical Center Madison, Wisconsin, United States, 53792 Collapse << |
NCT00471718 | Prostate Cancer | Phase 1 Phase 2 | Terminated(pharmaceutical comp... more >>any closed study because the treatment was not effective) Collapse << | - | United States, Tennessee ... more >> Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232-6838 Collapse << |
NCT00436852 | - | - | Active, not recruiting | - | - |
NCT00735878 | - | - | Terminated(data from a similar... more >> did not show efficacy.) Collapse << | - | - |
NCT00735878 | Non Small Cell Lung Cancer ... more >> Lung Cancer Collapse << | Phase 1 Phase 2 | Terminated(data from a similar... more >> did not show efficacy.) Collapse << | - | United States, New Hampshire ... more >> Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire, United States, 03756 Collapse << |
NCT00471718 | - | - | Terminated(pharmaceutical comp... more >>any closed study because the treatment was not effective) Collapse << | - | - |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网